Literature DB >> 27461717

Establishment and characterization of a novel human cholangiocarcinoma cell line with high metastatic activity.

Kwuntida Uthaisar1, Kulthida Vaeteewoottacharn1, Wunchana Seubwai2, Chutima Talabnin3, Kanlayanee Sawanyawisuth1, Sumalee Obchoei1, Ratthaphol Kraiklang4, Seiji Okada5, Sopit Wongkham1.   

Abstract

Cholangiocarcinoma (CCA) is a highly metastatic tumor, and the lung is a common site of metastasis. A greater understanding of the biology of metastases is needed to improve treatment outcomes. Herein, a highly metastatic human CCA subline, KKU-213L5 from an original cell line, KKU-213 that has marginally metastatic ability, was established and characterized. KKU-213L5 was selected in vivo through the fifth serial passage of pulmonary metastasized tissues via tail-vein injection in NOD/scid/Jak3 mice. The metastatic abilities of the KKU-213L5 cells were compared with the parental line in vitro and in vivo. The expression profile of this metastatic cell line was determined using real-time PCR. KKU-213L5 cells were found to possess higher metastatic phenotypes, i.e., growth rates, stem cell surface markers (CD133), migration and invasion characteristics when compared with the parental cells. Compared to the KKU-213 cells, KKU-213L5 cells formed larger tumors in subcutaneous xenografted mice and had a >10-fold increase in lung metastases in the tail-vein injected metastatic mouse model. Mice injected intravenously with KKU-213L5 cells had a significantly shorter survival. Analysis of the expressed genes related to progression of cancer revealed significant upregulation of anterior gradient protein-2 (AGR2) and suppression of KiSS-1 in the KKU-213L5 cells. The association of these two genes with metastasis was affirmed in CCA patient tissues since increased AGR2 expression and decreased KiSS-1 expression were found in higher stage patient tumors. In conclusion, a highly metastatic human CCA cell line was established and characterized. It is plausible that the differential expression between the parental KKU-213 and highly metastatic KKU-213L5 cells may be beneficial to classify novel genes associated with metastasis. The KKU-213L5 cell line should serve as a valued device for discovering the molecular mechanisms of CCA metastasis and enabling the search for an effective therapy for the unmet clinical need in CCA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27461717     DOI: 10.3892/or.2016.4974

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells.

Authors:  Charupong Saengboonmee; Chatchai Phoomak; Suangson Supabphol; Kyle R Covington; Oliver Hampton; Chaisiri Wongkham; Richard A Gibbs; Kazuo Umezawa; Wunchana Seubwai; Marie-Claude Gingras; Sopit Wongkham
Journal:  Life Sci       Date:  2020-10-07       Impact factor: 5.037

Review 2.  Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.

Authors:  Abdulkadir Isidan; Ali Yenigun; Daiki Soma; Eric Aksu; Kevin Lopez; Yujin Park; Arthur Cross-Najafi; Ping Li; Debjyoti Kundu; Michael G House; Sanjukta Chakraborty; Shannon Glaser; Lindsey Kennedy; Heather Francis; Wenjun Zhang; Gianfranco Alpini; Burcin Ekser
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

3.  Metastasis of cholangiocarcinoma is promoted by extended high-mannose glycans.

Authors:  Diane Dayoung Park; Chatchai Phoomak; Gege Xu; Laura P Olney; Khiem A Tran; Simon S Park; Nathan E Haigh; Guillaume Luxardi; Worachart Lert-Itthiporn; Michiko Shimoda; Qiongyu Li; Nobuyuki Matoba; Fernando Fierro; Sopit Wongkham; Emanual Maverakis; Carlito B Lebrilla
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-25       Impact factor: 11.205

4.  Role of laminin and cognate receptors in cholangiocarcinoma cell migration.

Authors:  Kittiya Islam; Parichut Thummarati; Pakkanun Kaewkong; Banchob Sripa; Tuangporn Suthiphongchai
Journal:  Cell Adh Migr       Date:  2021-12       Impact factor: 3.405

5.  Annexin A1 Is a Potential Prognostic Marker for, and Enhances the Metastasis of, Cholangiocarcinoma.

Authors:  Kwuntida U Kotepui; Sumalee Obchoei; Kulthida Vaeteewoottacharn; Seiji Okada; Sopit Wongkham; Kanlayanee Sawanyawisuth
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

6.  High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation.

Authors:  Chatchai Phoomak; Kulthida Vaeteewoottacharn; Atit Silsirivanit; Charupong Saengboonmee; Wunchana Seubwai; Kanlayanee Sawanyawisuth; Chaisiri Wongkham; Sopit Wongkham
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

Review 7.  Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type.

Authors:  Meng-Shin Shiao; Khajeelak Chiablaem; Varodom Charoensawan; Nuttapong Ngamphaiboon; Natini Jinawath
Journal:  Front Genet       Date:  2018-08-15       Impact factor: 4.599

8.  O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1.

Authors:  Chatchai Phoomak; Atit Silsirivanit; Dayoung Park; Kanlayanee Sawanyawisuth; Kulthida Vaeteewoottacharn; Chaisiri Wongkham; Eric W-F Lam; Chawalit Pairojkul; Carlito B Lebrilla; Sopit Wongkham
Journal:  Oncogene       Date:  2018-06-18       Impact factor: 9.867

9.  Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns.

Authors:  Arunya Jiraviriyakul; Worawat Songjang; Pongsathorn Kaewthet; Phachsita Tanawatkitichai; Punyapat Bayan; Sutatip Pongcharoen
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

10.  Andrographolide Inhibits Cholangiocarcinoma Cell Migration by Down-Regulation of Claudin-1 via the p-38 Signaling Pathway.

Authors:  Phorutai Pearngam; Supeecha Kumkate; Seiji Okada; Tavan Janvilisri
Journal:  Front Pharmacol       Date:  2019-07-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.